Clinical Trial Update: Rituximab as Second Line Treatment for ITP [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating rituximab as second-line treatment for immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Ostfold Hospital Trust | Conditions: Immune Thrombocytopenia (ITP) | Phase 3 | Status: COMPLETED